-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Previous studies have shown that the anti-tumor effects of chimeric antigen receptor-modified T cells ( CAR-T ) and natural killer (NK) cells targeting CD19 (CAR19) promote the treatment of relapsed/refractory B-cell malignancies Change
The anti-tumor effects of chimeric antigen receptor-modified T cells ( CAR-T ) and natural killer (NK) cells targeting CD19 (CAR19) have promoted the transformation of treatment strategies for relapsed/refractory B-cell malignancies
However, among patients treated with CAR-T (CAR19) targeting CD19, more than 50% of patients still have disease progression
In B acute lymphoblastic leukemia (B-ALL) cases, the 30-95% recurrence rate after CAR19 treatment is related to the loss of CD19 on the cell surface
- LO This study aimed to phase I clinical trial in relapsed / refractory B-ALL, and patient LBCL (NCT03233854) was tested targeting CD19 and / or CD22 bispecific CAR-T therapy
Changes in the composition and phenotype of CAR products
Changes in the composition and phenotype of CAR productsIn B-ALL patients (n=17), 100% of the patients responded to treatment, accompanied by 88% of minimal residual disease negative complete remission (CR); in LBCL patients (n=21), 62% The patient responded to treatment and had a CR of 29%
In B-ALL patients (n=17), 100% of the patients responded to treatment, accompanied by 88% of minimal residual disease negative complete remission (CR); in LBCL patients (n=21), 62% The patient responded to treatment and had a CR of 29%
CD19/22-CAR-T is active in LBCL and B-ALL
CD19/22-CAR-T is active in LBCL and B-ALLAll in all, the results of the study further show that the loss of antigen is the main cause of resistance to CAR-T cell therapy
Designing multi-specific CAR-T cells with cross-target equivalent potency may improve the efficacy of the therapy, and the production of cytokines is an important quality indicator of the efficacy of CAR-T therapy
CAR T cells with dual targeting of CD19 and CD22 in adult patients with recurrent or refractory B cell malignancies: a phase 1 trial.
Leave a message here
